GlassScriptPhysician profile
David Thomas Stark
NPI 1528491990
$1,274.64
in general payments reported to CMS, 2019-2025
10 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $122 · 2021: $70.26 · 2022: $348 · 2023: $271 · 2024: $86.40 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $293.30 | 2019-2025 | Eysuvis, Clareon |
| Sight Sciences, INC. | $291.75 | 2021-2024 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $229.35 | 2022-2023 | Amvisc, Envista Mx60 Iol |
| Biotissue Holdings INC. | $143.55 | 2023 | |
| Nova Eye, INC. | $83.76 | 2025 | |
| Allergan, INC. | $82.66 | 2020 | |
| Horizon Therapeutics Plc | $52.57 | 2022 | |
| Abbvie INC. | $44.05 | 2022 | |
| Glaukos Corporation | $38.92 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $14.73 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.